Last reviewed · How we verify
Erythrodermic psoriasis
Approved treatments
- Sotyktu · Bristol-Myers Squibb
Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis. - Spevigo · Boehringer Ingelheim Pharmaceuticals Inc
Spevigo works by blocking the interleukin-36 receptor, which plays a key role in the development of psoriasis symptoms. - Cimzia · UCB
Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity. - Remicade · Johnson & Johnson
Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses. - Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd.
- Remicade · Johnson & Johnson
Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding. - IXIFI · PFIZER INC
- Taltz · Yale University
- BIMZELX · UCB INC
- SPEVIGO · BOEHRINGER INGELHEIM PHARMACEUTICALS INC
- Taltz · Eli Lilly
Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor. - Skyrizi · AbbVie
Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response. - Remicade · Johnson & Johnson
Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage. - Bimzelx · Ucb Japan Co., Ltd.
Bimzelx works by binding to interleukin-17A, a protein that promotes inflammation, to reduce symptoms of psoriasis. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
- Cimzia · University of Washington
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Erythrodermic psoriasis patent landscape — cliff calendar, originator estates, attackable patents
- Erythrodermic psoriasis treatment landscape brief
- Erythrodermic psoriasis treatment updates RSS
Frequently asked questions about Erythrodermic psoriasis
What drugs treat Erythrodermic psoriasis?
Tracked treatments include Sotyktu, Spevigo, Cimzia, Remicade, IXIFI, Taltz, BIMZELX, SPEVIGO.
What is the treatment for Erythrodermic psoriasis?
Standard treatment for Erythrodermic psoriasis includes Sotyktu, Spevigo, Cimzia, Remicade, IXIFI. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Erythrodermic psoriasis patent cliff · Erythrodermic psoriasis CI report
- Treatment: Sotyktu · Bristol-Myers Squibb
- Treatment: Spevigo · Boehringer Ingelheim Pharmaceuticals Inc
- Treatment: Cimzia · UCB
- Treatment: Remicade · Johnson & Johnson
- Treatment: Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing